ad image

Company Info

MilliporeSigma

MilliporeSigma

CDMO

Overview

Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. Merck KGaA, Darmstadt, Germany holds the global rights to the "Merck" name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
MilliporeSigma
Contributions
58 Contributions1 / 3
Exploring New Possibilities with 3D Printing of Pharmaceuticals
3D Printing

Exploring New Possibilities with 3D Printing of Pharmaceuticals

Thomas Kipping, Ph.D.

MilliporeSigma

PAO-02-24-CL-11Feb 23, 2024
Viscosity Reduction with An Excipient Platform and Feasibility Testing Service
Viscosity Reduction

Viscosity Reduction with An Excipient Platform and Feasibility Testing Service

Alana Gouveia

MilliporeSigma

PAO-08-23-CL-03Aug 10, 2023
Preparing Today for a Potential Ban on Titanium Dioxide in Pharmaceutical Drug Products
Alternative Excipient

Preparing Today for a Potential Ban on Titanium Dioxide in Pharmaceutical Drug Products

Almut von der Brelie

MilliporeSigma

PAO-08-23-CL-01Aug 03, 2023
Enhanced Solubility through API Processing: Salt and Cocrystal Formation
API

Enhanced Solubility through API Processing: Salt and Cocrystal Formation

Thomas Briel, Ph.D.; David Luedeker, Ph.D.

MilliporeSigma

PAO-05-23-CL-04May 05, 2023
Advancing Extrusion-Based 3D Printing for Drug Production
3D Printing

Advancing Extrusion-Based 3D Printing for Drug Production

Thomas Kipping, Ph.D.; Xianghao Zuo, Ph.D.

MilliporeSigma

PAO-11-022-CL-14Nov 29, 2022
High-Intensity Sweeteners for Taste Optimization
Sweeteners

High-Intensity Sweeteners for Taste Optimization

Almut von der Brelie

MilliporeSigma

PAO-11-022-CL-12Nov 28, 2022
Raman Spectroscopy as a PAT Tool Advancing Biopharma Manufacturing
Real-Time Monitoring

Raman Spectroscopy as a PAT Tool Advancing Biopharma Manufacturing

Stacy Shollenberger

MilliporeSigma

PAO-09-022-CL-08Sep 30, 2022
MilliporeSigma
Manufacturing Investment

MilliporeSigma Announces Investment of More Than € 130 Million to Strengthen Manufacturing Capabilities in Molsheim, France

MilliporeSigma

PR-M09-22-02Sep 08, 2022
Regulatory Considerations for Lipid Excipients
Lipid Excipients

Regulatory Considerations for Lipid Excipients

Claudia Widmann; Estelle Beguin Ph.D.

MilliporeSigma

PAO-07-022-CL-04Aug 15, 2022
Assuring Excipient Quality for Parenteral Products
Excipient Quality Assurance

Assuring Excipient Quality for Parenteral Products

Lars Albermann, Ph.D.; Markus Greulich

MilliporeSigma

PA287Jul 28, 2022
Optimizing Fed-Batch Processes with Chemically Defined Media and Feeds
Biomanufacturing

Optimizing Fed-Batch Processes with Chemically Defined Media and Feeds

Jonathan Kaiser

MilliporeSigma

PAO-07-022-CL-02Jul 11, 2022
How the Developability Classification System and Advanced Excipients Enable the Formulation of Poorly Soluble APIs
Advanced Excipients

How the Developability Classification System and Advanced Excipients Enable the Formulation of Poorly Soluble APIs

Daniel Joseph Price, Ph.D.

MilliporeSigma

PAO-04-022-CL-07Apr 27, 2022
Better Bioprocessing Efficiency Through Centralized Orchestration
Bioprocessing

Better Bioprocessing Efficiency Through Centralized Orchestration

Aniruddha Bose

MilliporeSigma

PAO-03-022-CL-23Mar 29, 2022
Enabling Stable, High-Viscosity Injectable Drug Products with New Excipient Combinations
Excipients

Enabling Stable, High-Viscosity Injectable Drug Products with New Excipient Combinations

Tobias Rosenkranz, Ph.D.; Sara Kalman

MilliporeSigma

PAO-01-22-CL-02Mar 12, 2022
MilliporeSigma
Facility Acquisition

MilliporeSigma Announces Closing of Exelead Acquisition and Plans to Invest More Than € 500 Million in Technology Scale-Up

MilliporeSigma

PR-M02-22-20Feb 23, 2022
MilliporeSigma
Business Development

MilliporeSigma Announces Organizational Transformation to Strengthen CDMO Offering and Accelerate Future Growth

MilliporeSigma

PR-M02-22-03Feb 07, 2022
Improving the Handling and Safety of Pharmaceutical Raw Materials Through Dry Granulation

Improving the Handling and Safety of Pharmaceutical Raw Materials Through Dry Granulation

Thomas Briel, Ph.D.; Moritz Beck-Broichsitter, Ph.D.

MilliporeSigma

PA141Jan 28, 2022
Boosting Cell Densities and Productivity with Tailored Media in Seed Train
Biomanufacturing

Boosting Cell Densities and Productivity with Tailored Media in Seed Train

Melanie Brandl, Ph.D.

MilliporeSigma

PAO-11-21-CL-17Dec 03, 2021
Accelerating Biologics Development with High-Quality Protein Stabilization Excipients
Formulation

Accelerating Biologics Development with High-Quality Protein Stabilization Excipients

Balu Guduri; Nelli Erwin, Ph.D.

MilliporeSigma

PAO-11-21-CL-12Nov 18, 2021
Pandemic Playbook for Gene Therapy Manufacturing
Gene Therapy

Pandemic Playbook for Gene Therapy Manufacturing

Ratish Krishnan; David Loong, Ph.D.; Nargisse El-Hajjami, Ph.D.

MilliporeSigma

PAO-09-21-CL-14Sep 29, 2021
1 / 3